Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.
Catherine Shaffer
Advertisement
Catherine Shaffer is a contributing writer to BioPharm International, cathshaffer@gmail.com.
Articles by Catherine Shaffer
A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.
Advertisement
Latest Updated Articles
Ensuring the Biological Integrity of Raw MaterialsPublished: February 1st 2017 | Updated:
Cost Considerations Drive Lean Technology in Biopharmaceutical ManufacturingPublished: March 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
Regulatory Challenges for Global Manufacturing of Vaccines
4
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
5
